Last reviewed · How we verify
reverse hybrid therapy
reverse hybrid therapy is a Small molecule drug developed by Kaohsiung Veterans General Hospital.. It is currently in Phase 1 development. Also known as: pantoprazole 40mg, amoxicillin 1g, clarithromycin 500mg, metronidazole 500mg.
Reverse hybrid therapy involves combining multiple medications, including pantoprazole, bismuth, and antibiotics such as amoxicillin and clarithromycin, to treat various conditions. This treatment modality, which is classified as a small molecule therapy, has been studied in clinical trials for conditions including Helicobacter Pylori infection, HIV infections, and contraception.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | reverse hybrid therapy |
|---|---|
| Also known as | pantoprazole 40mg, amoxicillin 1g, clarithromycin 500mg, metronidazole 500mg, Pantoprazole |
| Sponsor | Kaohsiung Veterans General Hospital. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Gastrointestinal symptoms
- General symptoms
Key clinical trials
- Kuwa Free! - Live Free! (NA)
- Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With a Hybrid-Fractional Laser for Facial Rejuvenation (NA)
- Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)
- 14-day PCAB-based High-dose Dual Therapy and14-day PCAB-based Triple Therapy vs 14-day PPI-based Reverse Hybrid Therapy (PHASE4)
- Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy (NA)
- Comparing the Efficacy of 10-day Reverse Hybrid Therapy and 10-day Triple Therapy Plus Bismuth Therapy. (NA)
- Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt (PHASE4)
- Tailored Juice-guided Eradication Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- reverse hybrid therapy CI brief — competitive landscape report
- reverse hybrid therapy updates RSS · CI watch RSS
- Kaohsiung Veterans General Hospital. portfolio CI
Frequently asked questions about reverse hybrid therapy
What is reverse hybrid therapy?
Who makes reverse hybrid therapy?
Is reverse hybrid therapy also known as anything else?
What development phase is reverse hybrid therapy in?
What are the side effects of reverse hybrid therapy?
Related
- Manufacturer: Kaohsiung Veterans General Hospital. — full pipeline
- Also known as: pantoprazole 40mg, amoxicillin 1g, clarithromycin 500mg, metronidazole 500mg, Pantoprazole
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing